Xin Lang Zheng Quan·2025-09-08 01:29Group 1 - On September 5, Tiger Med's stock rose by 6.66%, with a trading volume of 950 million yuan [1] - The financing data shows that on the same day, Tiger Med had a financing purchase amount of 47.28 million yuan and a financing repayment of 98.82 million yuan, resulting in a net financing outflow of 51.55 million yuan [1] - As of September 5, the total balance of margin trading for Tiger Med was 625 million yuan, with the financing balance at 620 million yuan, accounting for 1.26% of the circulating market value, which is below the 10th percentile level over the past year [1] Group 2 - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, provides professional clinical research services for domestic and international pharmaceutical and health-related products [2] - The company's main business revenue composition includes 52.60% from clinical trial-related services and laboratory services, and 45.21% from clinical trial technical services [2] - For the first half of 2025, Tiger Med reported an operating income of 3.25 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 383 million yuan, a year-on-year decrease of 22.22% [2] Group 3 - Since its A-share listing, Tiger Med has distributed a total of 2.458 billion yuan in dividends, with 1.154 billion yuan distributed in the last three years [3] - As of June 30, 2025, the top ten circulating shareholders of Tiger Med include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3]